Início › Câncer de Estômago › Pensilvânia › Pittsburgh
Ensaios clínicos de Câncer de Estômago em Pittsburgh, PA
14 estudos para Câncer de Estômago estão buscando participantes em locais em Pittsburgh e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Distance-Based Exercise to Preserve Function and Prevent Disability
Recrutando
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RecrutandoFase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
RecrutandoFase 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecrutandoFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecrutandoFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
RecrutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecrutandoFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecrutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecrutandoFase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RecrutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RecrutandoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
RecrutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RecrutandoFase 1
- AHN West Penn Hospital, Pittsburgh
Ensaios de Câncer de Estômago em outras cidades
- Houston, TX42 estudos
- Boston, MA32 estudos
- New York City, NY31 estudos
- Nashville, TN28 estudos
- Baldwin Park, CA22 estudos
- Los Angeles, CA22 estudos
- Arlington, VA20 estudos
- Dallas, TX19 estudos
- San Antonio, TX19 estudos
- St. Louis, MO18 estudos
- Grand Rapids, MI18 estudos
- Chicago, IL16 estudos
Outros estudos em Pittsburgh
- Câncer de Pulmão de Não Pequenas Células48 estudos
- Câncer (todos os tipos)41 estudos
- Câncer de Mama39 estudos
- Câncer Colorretal32 estudos
- Câncer Metastático31 estudos
- Melanoma31 estudos
- Câncer de Ovário30 estudos
- Câncer Endometrial23 estudos
- Câncer de Próstata23 estudos
- Câncer de Pulmão23 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço22 estudos
- Acidente Vascular Cerebral22 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.